Raphael Pharmaceutical Overview
Get informed when a big investor buys or sells
+ Follow92.55
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
Raphael Pharmaceutical (RAPH) currently reports a PEG ratio of 92.55. That is above the sector sector average of 9.98. Use the charts on this page to explore Raphael Pharmaceutical's PEG ratio history and peer comparisons.
Raphael Pharmaceutical's PEG ratio of 92.55 is higher than the its sector sector average of 9.98. That is roughly 827.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The PEG ratio is a valuation multiple that relates Raphael Pharmaceutical's market price to a fundamental measure such as earnings, sales, or book value. At 92.55, RAPH can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current PEG ratio of 92.55, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 9.98. From there, open related valuation or income-statement pages for Raphael Pharmaceutical, and consider following RAPH for alerts when major investors trade the stock.
